| Dr Peter E Bloom Jr, MD | |
|
25 Newell Rd, Suite E36, Bristol, CT 06010-5100 | |
| (860) 583-9252 | |
| Not Available |
| Full Name | Dr Peter E Bloom Jr |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 20 Years |
| Location | 25 Newell Rd, Bristol, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447468954 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 048599 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospital | Bristol, CT | Hospital |
| The Hospital Of Central Connecticut | New britain, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Connecticut Gi Pc | 9830110758 | 185 |
News Archive
Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.
The London School of Hygiene & Tropical Medicine is launching a new series of debates explores the dilemmas of humanitarianism on 15 November in London.
Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. The discovery, published in Cancer Cell, will help to identify unique aspects of melanoma that could contribute to determine the risk of developing metastasis in patients with this disease.
Genentech, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. According to the American Cancer Society, kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, approximately 13,000 Americans will die from the disease.
A study by the Center for Responsive Politics and the Sunlight Foundation has found that key lawmakers have received significant contributes not only from major health industry companies - who often lead in contributions to members of Congress - but also from their lobbyists, who have contributed from their personal resources, The Washington Post reports.
› Verified 5 days ago
| Entity Name | Connecticut Gi Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023124625 PECOS PAC ID: 9830110758 Enrollment ID: O20070112000011 |
News Archive
Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.
The London School of Hygiene & Tropical Medicine is launching a new series of debates explores the dilemmas of humanitarianism on 15 November in London.
Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. The discovery, published in Cancer Cell, will help to identify unique aspects of melanoma that could contribute to determine the risk of developing metastasis in patients with this disease.
Genentech, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. According to the American Cancer Society, kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, approximately 13,000 Americans will die from the disease.
A study by the Center for Responsive Politics and the Sunlight Foundation has found that key lawmakers have received significant contributes not only from major health industry companies - who often lead in contributions to members of Congress - but also from their lobbyists, who have contributed from their personal resources, The Washington Post reports.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter E Bloom Jr, MD 25 Newell Rd, Suite E36, Bristol, CT 06010-5100 Ph: (860) 583-9252 | Dr Peter E Bloom Jr, MD 25 Newell Rd, Suite E36, Bristol, CT 06010-5100 Ph: (860) 583-9252 |
News Archive
Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.
The London School of Hygiene & Tropical Medicine is launching a new series of debates explores the dilemmas of humanitarianism on 15 November in London.
Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. The discovery, published in Cancer Cell, will help to identify unique aspects of melanoma that could contribute to determine the risk of developing metastasis in patients with this disease.
Genentech, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. According to the American Cancer Society, kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, approximately 13,000 Americans will die from the disease.
A study by the Center for Responsive Politics and the Sunlight Foundation has found that key lawmakers have received significant contributes not only from major health industry companies - who often lead in contributions to members of Congress - but also from their lobbyists, who have contributed from their personal resources, The Washington Post reports.
› Verified 5 days ago
Ronald S Green, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 25 Newell Rd, Suite E-36, Bristol, CT 06010 Phone: 860-583-9252 Fax: 860-585-9848 | |
Daniel Norman Smiley, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 25 Newell Rd, Suite E-36, Bristol, CT 06010 Phone: 860-583-9252 Fax: 860-585-9848 | |
Dr. Michael Owen Richards, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 41 Brewster Rd, Bristol, CT 06010 Phone: 860-585-3000 | |
Michael Stephen Ptaszynski, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 25 Newell Rd, #d-25, Bristol, CT 06010 Phone: 860-314-6020 Fax: 860-314-6024 | |
Dr. Robert C Debiase, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 25 Newell Rd, Suite D24, Bristol, CT 06010 Phone: 860-582-3235 Fax: 860-582-0692 | |
Dr. Nandini Ravindra Menon, M.D Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 123 Maple St, Bristol, CT 06010 Phone: 860-584-8021 Fax: 860-584-9021 | |
Christopher Wakem, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 44 Brewster Road, Hem/oncology Dept., Level A, Bristol, CT 06010 Phone: 860-585-3000 Fax: 860-585-3907 |